vTv Therapeutics Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 13, 2024. vTv is a clinical-stage biopharmaceutical company with no approved products; its lead candidate is cadisegliatin (TTP399), an oral liver-selective glucokinase activator being developed as an adjunct to insulin for type 1 diabetes (T1D).
Financial performance and liquidity
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Revenue | $0 | $2.018 million | 2022 revenue reflected a Huadong development milestone; no product-sales revenue in either year. |
| Research and development | $13.595 million | $12.357 million | Up $1.238 million, mainly from cadisegliatin drug-product and trial-preparation costs, plus indirect and other project costs. |
| General and administrative | $11.907 million | $12.201 million | Down $0.294 million; lower legal and severance costs partly offset by higher payroll and other costs. |
| Operating loss | $25.502 million | $22.540 million | Loss widened as revenue fell to zero and operating expenses increased. |
| Net loss attributable to vTv Therapeutics Inc. | $20.250 million | $19.164 million | Widened by $1.086 million. Consolidated net loss before noncontrolling interests was $25.966 million in 2023. |
| Basic and diluted loss per Class A share | $9.71 | $9.98 | Reverse-split-adjusted figures (1-for-40 split in November 2023). |
| Cash and cash equivalents at year-end | $9.446 million | $12.126 million | Down $2.680 million. |
| Net cash used in operating activities | $19.081 million | $16.022 million | Use increased $3.059 million; 2022 included $6.760 million of cash received related to contract liabilities. |
| Net cash from investing activities | $4.404 million | $(0.021) million | 2023 proceeds came from selling the Reneo investment. |
| Net cash from financing activities | $11.997 million | $14.754 million | 2023 primarily included the $12.0 million early repayment of the G42 promissory note. |
Balance sheet and profitability: Total assets were $11.018 million and total liabilities were $29.567 million at year-end. Current assets were $10.657 million versus current liabilities of $10.619 million. Liabilities included $18.669 million of noncurrent contract liabilities, primarily deferred consideration under the G42 arrangement. Notes payable were $191,000, all current; the filing reports no material interest-rate exposure. Accumulated deficit was $281.042 million. Gross margin is not meaningful because the company reported no revenue in 2023.
Post-year-end funding: On February 27, 2024, the company closed a private placement that generated approximately $51.0 million in gross proceeds before expenses, through Class A shares and pre-funded warrants. Investors also received a right to purchase up to $30.0 million of additional Class A shares 18 months after closing. A separate ATM facility permits up to $50.0 million of sales, subject to public-float limitations and a 3% commission. Management expects available resources to fund operations into the first quarter of 2026 under its current plan, while noting that additional funding may be needed.
Material changes, programs, and outlook
- Cadisegliatin in T1D: The company reports that Phase 2 SimpliciT-1 showed statistically significant HbA1c improvement versus placebo and a 40% decrease in severe and symptomatic hypoglycemia frequency. FDA Breakthrough Therapy designation was granted in 2021. The company describes a 150-patient U.S. Phase 3 trial focused on Level 2 and Level 3 hypoglycemia, with HbA1c as a key secondary endpoint and 12 months of treatment. The protocol was submitted to the FDA on February 29, 2024; enrollment completion is expected by Q4 2024 and one-year topline data by Q1 2026. The filing’s statements that the trial has been initiated and that its protocol was submitted in February 2024 do not clearly establish the trial’s actual start date.
- Further cadisegliatin development: The company expects to design two international registrational T1D studies for potential starts in 2026. With G42, it expects a 450-patient Phase 2 study in insulin-using patients with type 2 diabetes (T2D) in the Middle East to begin in 2024. These are forward-looking expectations, not reported trial outcomes.
- Portfolio and collaboration changes: Huadong notified vTv in December 2023 of its intent to terminate the GLP-1r license; termination remained subject to a negotiated agreement, expected in the first half of 2024. Anteris’ HPP971 license termination became effective December 24, 2023, and Anteris liquidated and ceased business; vTv recorded a $4.245 million impairment of its investment. vTv sold its Reneo shares for approximately $4.404 million and recognized a $3.061 million gain. Reneo separately reported that its pivotal mavodelpar study in primary mitochondrial myopathy did not meet its primary or secondary efficacy endpoint.
- Other pipeline: The company continues to describe TTP273, HPP3033, and HPP737 as research or development assets, while actively seeking licensing arrangements for other programs. HPP737 development in China and Pacific Rim territories is licensed to Newsoara; potential milestones and royalties are contingent. No approval or commercialization revenue is reported for these candidates.
- Guidance and funding: Management prioritizes cadisegliatin and expects continuing losses and negative operating cash flow while it conducts development. It is pursuing financing, partnering, licensing, and monetization options. The filing states there was no substantial doubt about going concern for at least 12 months from issuance, following the 2024 private placement; this is distinct from the $9.446 million cash balance at December 31, 2023.
Risks, contingencies, and unusual items
- Clinical and regulatory risks remain substantial: cadisegliatin is investigational, later-stage results may differ from Phase 2, trial enrollment or regulatory review may be delayed, and approval is uncertain. The filing identifies potential safety, efficacy, manufacturing, and trial-execution risks.
- The company has no product revenue and expects continued losses. Future funding may dilute shareholders or require licensing or other concessions; the private placement warrants and possible ATM sales add potential dilution.
- Nasdaq notified the company in December 2023 that it did not meet the $35 million minimum market value of listed securities requirement. The stated compliance deadline was June 10, 2024; failure to regain compliance could result in delisting.
- vTv relies on third parties for clinical execution and manufacturing, has no multiple sources for candidate components, and does not operate manufacturing facilities.
- MacAndrews held approximately 56% of combined voting power at December 31, 2023. The company also has investor governance arrangements, related-party relationships, and a tax receivable agreement that generally entitles M&F to 85% of specified realized or deemed tax savings.
- The G42 agreement may require, upon FDA approval, either $30.0 million in cash or Class A shares of equivalent value, at G42’s option, subject to agreement terms. vTv may also owe Novo Nordisk milestone payments and royalties if specified development, approval, or sales conditions are met.
- No material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the external auditor did not audit internal control effectiveness because the company is not required to obtain that attestation.
Most important facts for investors to verify
- Whether the cadisegliatin Phase 3 trial is active, its enrollment progress, and whether the Q4 2024 enrollment and Q1 2026 data targets remain achievable.
- Post-placement cash, actual operating cash burn, and whether management’s runway estimate into Q1 2026 remains valid after trial costs and offering expenses.
- The final status and terms of Huadong’s proposed termination, and any material effect on TTP273 rights or future economics.
- Nasdaq listing compliance status and any subsequent actions or deadlines.
- The potential share dilution from pre-funded warrants, future ATM sales, the additional $30.0 million investor purchase right, and other outstanding equity instruments.
- Any updates to the G42 T2D trial, financing or licensing plans, material safety findings, or the contingent $30.0 million G42 payment obligation upon FDA approval.